News & Updates

$Faecal microbiota transplantation beneficial for survival in patients with refractory SFCDI$

Faecal microbiota transplantation beneficial for survival in patients with refractory SFCDI

17 Feb 2020

An inpatient faecal microbiota transplantation programme yields substantial reductions in Clostridioides difficile infection (CDI)-related mortality in patients with refractory severe or fulminant (SF) CDI, a study has found.

Faecal microbiota transplantation beneficial for survival in patients with refractory SFCDI

17 Feb 2020

Tenapanor proven safe, effective in treatment of IBS with constipation

16 Feb 2020

Treatment with tenapanor 50 mg twice daily (bid) results in improvement of constipation-predominant irritable bowel syndrome (IBS-C) symptoms and is generally well tolerated, a phase III study has shown.

Tenapanor proven safe, effective in treatment of IBS with constipation

16 Feb 2020

Small intestinal bacterial overgrowth linked to irritable bowel syndrome

15 Feb 2020

An association appears to exist between irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO), suggest the results of a systematic review and meta-analysis. However, the overall quality of evidence is low.

Small intestinal bacterial overgrowth linked to irritable bowel syndrome

15 Feb 2020

Donor selection for FMT key to sustained UC remission

14 Feb 2020 by

Donor selection for faecal microbiota transplant (FMT) can make a difference to maintenance of long-term remission in patients with ulcerative colitis (UC), reveals a study presented at the 2020 Crohn's & Colitis Congress (CCC).

Donor selection for FMT key to sustained UC remission

14 Feb 2020

Apremilast may be beneficial to patients with active ulcerative colitis

14 Feb 2020

The use of apremilast in the treatment of patients with active ulcerative colitis (UC) falls short of inducing clinical remission, although it leads to marked improvements in clinical and endoscopic features and markers of inflammation, according to the results of a phase II trial.

Apremilast may be beneficial to patients with active ulcerative colitis

14 Feb 2020

Does antioxidants supplementation improve pancreatic functions in chronic pancreatitis?

14 Feb 2020

Chronic pancreatitis patients taking antioxidants (AO) supplementation show a sustained increase in blood levels of AO, but no additional benefit is seen on endocrine and exocrine functions, markers of fibrosis, oxidative stress (OS) and inflammation, nutritional status, pain, and quality of life (QOL) when compared with those on placebo, according to a study.

Does antioxidants supplementation improve pancreatic functions in chronic pancreatitis?

14 Feb 2020

Sequential more cost-effective than standard triple therapy for H. pylori infection

14 Feb 2020

A 10-day or 14-day sequential therapy strategy is more cost-effective than a conventional triple therapy in the management of patients with Helicobacter pylori infection, in addition to being more effective in terms of eradication of infection, as reported in a study from Egypt.

Sequential more cost-effective than standard triple therapy for H. pylori infection

14 Feb 2020

Ustekinumab dose escalation: An option for nonresponsive Crohn’s?

13 Feb 2020 by

Dose escalation of ustekinumab appears to be an effective option for Crohn’s disease (CD) patients with luminal and perianal manifestations who were nonresponsive to previous therapies, according to a study presented at the Crohn's & Colitis Congress (CCC) 2020.

Ustekinumab dose escalation: An option for nonresponsive Crohn’s?

13 Feb 2020

Mirikizumab may reduce bowel urgency in moderate-to-severe ulcerative colitis

13 Feb 2020 by

The humanized monoclonal antibody mirikizumab appears to reduce bowel movement urgency among patients with moderate to severely active ulcerative colitis (UC), according to a study presented at the Crohn’s and Colitis Congress 2020.

Mirikizumab may reduce bowel urgency in moderate-to-severe ulcerative colitis

13 Feb 2020

Female gender, dosage predict gastrin elevation in GERD patients on long-term PPI therapy

13 Feb 2020

Dosage and female gender are associated with the development of gastrin elevation following proton pump inhibitor (PPI) therapy, a recent study has found. Moreover, fasting serum gastrin significantly correlates with PPI dosage over weight and over body surface area.

Female gender, dosage predict gastrin elevation in GERD patients on long-term PPI therapy

13 Feb 2020

News & Updates

Filter by Specialty:

Specialty:

Faecal microbiota transplantation beneficial for survival in patients with refractory SFCDI

Faecal microbiota transplantation beneficial for survival in patients with refractory SFCDI

Tenapanor proven safe, effective in treatment of IBS with constipation

Tenapanor proven safe, effective in treatment of IBS with constipation

Small intestinal bacterial overgrowth linked to irritable bowel syndrome

Small intestinal bacterial overgrowth linked to irritable bowel syndrome

Donor selection for FMT key to sustained UC remission

Donor selection for FMT key to sustained UC remission

Apremilast may be beneficial to patients with active ulcerative colitis

Apremilast may be beneficial to patients with active ulcerative colitis

Does antioxidants supplementation improve pancreatic functions in chronic pancreatitis?

Does antioxidants supplementation improve pancreatic functions in chronic pancreatitis?

Sequential more cost-effective than standard triple therapy for H. pylori infection

Sequential more cost-effective than standard triple therapy for H. pylori infection

Ustekinumab dose escalation: An option for nonresponsive Crohn’s?

Ustekinumab dose escalation: An option for nonresponsive Crohn’s?

Mirikizumab may reduce bowel urgency in moderate-to-severe ulcerative colitis

Mirikizumab may reduce bowel urgency in moderate-to-severe ulcerative colitis

Female gender, dosage predict gastrin elevation in GERD patients on long-term PPI therapy

Female gender, dosage predict gastrin elevation in GERD patients on long-term PPI therapy